Venkat comes with a very rich and global experience of more than 25 years, successfully leading organizations in the biotech and cosmoceutics businesses. He held top management roles in the biotech and pharmaceutical companies like Shantha Biotechnics (A Sanofi Company) and Aurobindo Pharma and he immensely contributed to their all-round growth. He was instrumental in creating market focus and orchestrating vaccine portfolio strategy in Shantha Biotech - a biosimilar and vaccine company, and it was eventually acquired by Sanofi for $800 million USD. He has been a part of significant revenue growth and value creation in Aurobindo Pharma in the global business segment of APIs and finished dosage form products in multiple therapy areas.
He has held CEO and President roles in Emami and Cavinkare, cosmoceutical and consumer product companies in India with global operations, creating value and growing them significantly with an all rounded approach. During his stint at Emami (a listed company) as CEO, the company's market cap increased from $ 300 MN to $ 1.2 BN. During the early part of his career, he created some very successful Cosmoceutical brands in Cavinkare, and built the organization with a 10X revenue increase in 6 years’ time.
He comes with core strengths in Strategy, Innovation, Technology, Commercialization, Organization building, Finance, M&A. Venkat has received his B.Tech in Mechanical Engineering and an MBA from Indian Institute of Management – Ahmedabad, India.
Contact Information: firstname.lastname@example.org
Dr. Bhaskar Chaudhuri currently works with Frazier Healthcare as an Operating Partner. Previously, Dr. Chaudhuri served as the President of Valeant Pharmaceuticals International through the end of 2010. He joined Valeant through the Company’s acquisition of Dow Pharmaceutical Sciences, Inc. in late 2008, where Dr. Chaudhuri served as President and Chief Executive Officer. Dr. Chaudhuri serves on the board of Silvergate Pharmaceuticals.
Before joining Dow, Dr. Chaudhuri worked at Mylan Pharmaceuticals in different capacities including Executive Vice President of Scientific Affairs (Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories) and as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri joined Mylan through the acquisition of Penederm Inc., where he was the Vice President of Research and Development.
Dr. Chaudhuri has over 20 years of experience in pharmaceutical management and currently also serves on the Board of two companies. He holds a Doctorate in Physical Pharmacy, a Master of Science in Industrial Pharmacy and a Bachelor’s of Science in Pharmacy.
Kumar Shiralagi has a 10-plus year track record of managing high-performing investments and exits. He is a managing director at Kalaari Capital, where he serves on ten company boards and has been involved with more than 25 companies - advising investments, serving on boards, and managing exits. From 2003 to 2007, he was Country Director of Intel Capital India. He is a Senior Member of IEEE and a Charter Member of TiE. He has published more than 60 technical papers, holds 23 U.S. patents, and co-founded Lytek Corporation, a semiconductor laser manufacturer.
Kumar graduated with an engineering degree from NIT Karnataka and a PhD in electrical engineering from Arizona State University. He also holds an MBA from the Thunderbird School of Global Management.
Krishna K. Gupta is the founder and managing partner of Romulus Capital, which he founded more than a decade ago while at MIT. He focuses on "building rather than betting on" technology and science-based companies. He particularly enjoys partnering with companies (mostly B2B) that have innovative technology or science at the core of their value propositions; as such, he sits on the boards of companies that have spun out of MIT, Harvard, Stanford, and Cambridge. Prior to Romulus, Krishna spent time at McKinsey & Company and JPMorgan.
Krishna received SB degrees in Materials Science and Engineering and Management Science from the Massachusetts Institute of Technology (MIT). He is a graduate of Phillips Academy Andover. To learn more about Krishna, visit his profile here
Alan Rosling founded Griffin Growth Partners, a consulting business focused on assisting international companies with Asian strategy. He has advised a large number of international clients on growth strategies for the region as well as Indian companies on internationalisation. Alan also is co-founder and a Director of Kiran Energy, one of India’s leading independent solar power producers.
He is a Non Executive Director of Coats Plc and LNGaz, a Canadian small-scale LNG company which he co-founded. LNGaz has entered a Joint Venture with Stolt-Nielsen to develop an LNG facility in Quebec. He is also Senior Advisor to Navam Capital, an early stage technology venture fund.
Alan was an Executive Director of Tata Sons Limited for five years from 2004 and was the Director responsible for internationalising the Tata Group. From 1998 to 2003 he was Chairman of the Jardine Matheson Group in India. His earlier career included the Policy Unit at No.10 Downing Street; Strategy Director at United Distillers, CEO of a division of Courtaulds Textiles and S.G. Warburg.
Alan was educated at Cambridge University and the Harvard Business School.
Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.